Moberg Pharma AB announced that the company has completed the divestment of the Jointflex, Fergon and Vanquish brands to Strides Pharma Inc. for a total consideration of $10.4 million, whereof $0.4 million comprises inventory value.

Moberg Pharma’s strategy is to build value through profitable growth of strategic brands, increasing the value of pipeline assets and acquisitions. Completing the divestment of the three brands enables Moberg Pharma to focus on its core business.

Moberg Pharma disclosed this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act.

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal, Kerasal Nail, Balmex, Domeboro. Kerasal Nail (Emtrix or Nalox in certain markets) is a leading OTC treatment of nail disorders in the US, Canada and several EU markets and is currently being launched in Southeast Asia.